Special remarks: Labeled with biotin. human Abeta and beta-CTF N-terminal specific. Reacts with both soluble and fibrillar Abeta to a similar degree
No cross reactivity with non-cleaved APP.
Very low cross reactivity with mouse and rat Abeta (<10%).

Alzheimer's disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide(A beta), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by beta-secretase and a putative gamma secretase. Increased release of the 'longer forms' of A beta peptide, A beta 42 or A beta 43, which have a greater tendency to aggregate than A beta 40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles, or may involve other, still undiscovered, factors, Many researchers theorize that it is this increased release of A beta 42/A beta 43 which leads to the abnormal deposition of A beta and the associated neurotoxicity in the brains of affected individuals.